miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22 | Zendy

Jun Li | Zendy; Mingjie Lu | Zendy; Jin Jiao | Zendy; Xiyi Lu | Zendy; Tongpeng Xu | Zendy; Shidai Jin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

miR-449a Suppresses Tamoxifen Resistance in Human Breast Cancer Cells by Targeting ADAM22

Author(s) -

Jun Li,

Mingjie Lu,

Jin Jiao,

Xiyi Lu,

Tongpeng Xu,

Shidai Jin

Publication year - 2018

Publication title -

cellular physiology and biochemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.486

H-Index - 87

eISSN - 1421-9778

pISSN - 1015-8987

DOI - 10.1159/000493964

Subject(s) - tamoxifen , breast cancer , cancer research , microrna , gene silencing , estrogen receptor , selective estrogen receptor modulator , cancer , antiestrogen , biology , medicine , gene , genetics

Most of estrogen receptor positive breast cancer patients respond well initially to endocrine therapies, but often develop resistance during treatment with selective estrogen receptor modulators (SERMs) such as tamoxifen. Altered expression and functions of microRNAs (miRNAs) have been reportedly associated with tamoxifen resistance. Thus, it is necessary to further elucidate the function and mechanism of miRNAs in tamoxifen resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research